Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - MSN

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress  MSN

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - MSN

Click here to get full coverage on Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewswire

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors  GlobeNewswire

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewswire

Click here to get full coverage on Revolution Medicines Insider Ups Holding During Year - simplywall.st

Revolution Medicines Insider Ups Holding During Year  simplywall.st

Revolution Medicines Insider Ups Holding During Year - simplywall.st

Click here to get full coverage on Revolution Medicines Launches Major Cancer Trial: 3 RAS Inhibitors Combined with Novel PD-1 Therapy - Stock Titan

Revolution Medicines Launches Major Cancer Trial: 3 RAS Inhibitors Combined with Novel PD-1 Therapy  Stock Titan

Revolution Medicines Launches Major Cancer Trial: 3 RAS Inhibitors Combined with Novel PD-1 Therapy - Stock Titan

Click here to get full coverage on Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...  Yahoo Finance

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Click here to get full coverage on Revolution Medicines (RVMD) Enters Partnership with Summit Therapeutics - GuruFocus

Revolution Medicines (RVMD) Enters Partnership with Summit Therapeutics  GuruFocus

Revolution Medicines (RVMD) Enters Partnership with Summit Therapeutics - GuruFocus

Click here to get full coverage on Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Value Index - MarketScreener

Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Value Index  MarketScreener

Revolution Medicines, Inc.(NasdaqGS: RVMD) added to Russell Midcap Value Index - MarketScreener

Click here to get full coverage on Revolution Medicines' Royalty Pharma Deal: A Strategic Masterstroke for Oncology Dominance - AInvest

Revolution Medicines' Royalty Pharma Deal: A Strategic Masterstroke for Oncology Dominance  AInvest

Revolution Medicines' Royalty Pharma Deal: A Strategic Masterstroke for Oncology Dominance - AInvest

Click here to get full coverage on Revolution Medicines Lands Massive $2B Deal to Advance Revolutionary Cancer Treatment Program - Stock Titan

Revolution Medicines Lands Massive $2B Deal to Advance Revolutionary Cancer Treatment Program  Stock Titan

Revolution Medicines Lands Massive $2B Deal to Advance Revolutionary Cancer Treatment Program - Stock Titan

Click here to get full coverage on Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?  Yahoo Finance

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Yahoo Finance

Click here to get full coverage on Revolution Medicines Director Weber Resigns Amid Tango Therapeutics Trial Launch | RVMD SEC Filing - Form 8-K - Stock Titan

Revolution Medicines Director Weber Resigns Amid Tango Therapeutics Trial Launch | RVMD SEC Filing - Form 8-K  Stock Titan

Revolution Medicines Director Weber Resigns Amid Tango Therapeutics Trial Launch | RVMD SEC Filing - Form 8-K - Stock Titan

Click here to get full coverage on We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth  Yahoo Finance

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth - Yahoo Finance

Click here to get full coverage on Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - GlobeNewswire

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting  GlobeNewswire

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - GlobeNewswire

Click here to get full coverage on FDA Breakthrough: Revolutionary Pancreatic Cancer Drug Targets Critical KRAS Mutations in Late-Stage Patients - Stock Titan

FDA Breakthrough: Revolutionary Pancreatic Cancer Drug Targets Critical KRAS Mutations in Late-Stage Patients  Stock Titan

FDA Breakthrough: Revolutionary Pancreatic Cancer Drug Targets Critical KRAS Mutations in Late-Stage Patients - Stock Titan

Click here to get full coverage on Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan

Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums  Stock Titan

Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan

Click here to get full coverage on Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan

Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline  Stock Titan

Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan

Click here to get full coverage on Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...  Yahoo Finance

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Click here to get full coverage on Why Revolution Medicines, Inc. (RVMD) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Why Revolution Medicines, Inc. (RVMD) Is Among the Best Healthcare Stocks To Buy According to Analysts  Yahoo Finance

Why Revolution Medicines, Inc. (RVMD) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Click here to get full coverage on Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History - Seeking Alpha

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History  Seeking Alpha

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History - Seeking Alpha

Click here to get full coverage on Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress  GlobeNewswire

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire

Click here to get full coverage on Revolution Medicines (RVMD) Maintains Buy Rating as Analyst Reiterates Price Target | RVMD Stock News - GuruFocus

Revolution Medicines (RVMD) Maintains Buy Rating as Analyst Reiterates Price Target | RVMD Stock News  GuruFocus

Revolution Medicines (RVMD) Maintains Buy Rating as Analyst Reiterates Price Target | RVMD Stock News - GuruFocus

Click here to get full coverage on Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha

Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD)  Seeking Alpha

Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha

Click here to get full coverage on Revolution Medicines (RVMD) Receives - GuruFocus

Revolution Medicines (RVMD) Receives  GuruFocus

Revolution Medicines (RVMD) Receives - GuruFocus

Click here to get full coverage on (RVMD) Proactive Strategies - news.stocktradersdaily.com

(RVMD) Proactive Strategies  news.stocktradersdaily.com

(RVMD) Proactive Strategies - news.stocktradersdaily.com

Click here to get full coverage on Revolution Medicines (RVMD) Secures $2B Funding with Royalty Pha - GuruFocus

Revolution Medicines (RVMD) Secures $2B Funding with Royalty Pha  GuruFocus

Revolution Medicines (RVMD) Secures $2B Funding with Royalty Pha - GuruFocus

Click here to get full coverage on Revolution Medicines Secures Massive $862.5M in Upsized Public Offering - Stock Titan

Revolution Medicines Secures Massive $862.5M in Upsized Public Offering  Stock Titan

Revolution Medicines Secures Massive $862.5M in Upsized Public Offering - Stock Titan

Click here to get full coverage on Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025  GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire

Click here to get full coverage on Revolution Medicines (RVMD) Earns FDA Breakthrough Status for Ca - GuruFocus

Revolution Medicines (RVMD) Earns FDA Breakthrough Status for Ca  GuruFocus

Revolution Medicines (RVMD) Earns FDA Breakthrough Status for Ca - GuruFocus

Click here to get full coverage on Revolution Medicines (RVMD) Gains After FDA Grants Breakthrough Status - GuruFocus

Revolution Medicines (RVMD) Gains After FDA Grants Breakthrough Status  GuruFocus

Revolution Medicines (RVMD) Gains After FDA Grants Breakthrough Status - GuruFocus

Click here to get full coverage on Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - Nasdaq

Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround  Nasdaq

Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround - Nasdaq

Click here to get full coverage on Revolution Medicines Secures Massive $750M Public Offering with Upsized Share Sale - Stock Titan

Revolution Medicines Secures Massive $750M Public Offering with Upsized Share Sale  Stock Titan

Revolution Medicines Secures Massive $750M Public Offering with Upsized Share Sale - Stock Titan

Click here to get full coverage on Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans  simplywall.st

Revolution Medicines (NASDAQ:RVMD) Is In A Good Position To Deliver On Growth Plans - simplywall.st

Click here to get full coverage on Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference  GlobeNewswire

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Click here to get full coverage on Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - Insider Monkey

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now  Insider Monkey

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - Insider Monkey

Click here to get full coverage on Revolution Medicines Holds Annual Stockholders Meeting - TipRanks

Revolution Medicines Holds Annual Stockholders Meeting  TipRanks

Revolution Medicines Holds Annual Stockholders Meeting - TipRanks

Click here to get full coverage on Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now  Yahoo Finance

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance

Click here to get full coverage on Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) - Seeking Alpha

Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade)  Seeking Alpha

Revolution Medicines: New Data Underscore A True Cancer Revolution (Upgrade) - Seeking Alpha

Click here to get full coverage on Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - GlobeNewswire

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers  GlobeNewswire

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers - GlobeNewswire

Click here to get full coverage on Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks - Yahoo Finance

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks  Yahoo Finance

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks - Yahoo Finance

Click here to get full coverage on Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan

Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results  Stock Titan

Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan

Click here to get full coverage on Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD) - Seeking Alpha

Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD)  Seeking Alpha

Revolution Medicines: Risky Buy On Recent Share Price Dip (NASDAQ:RVMD) - Seeking Alpha

Click here to get full coverage on Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds - Benzinga

Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds  Benzinga

Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds - Benzinga

Click here to get full coverage on Revolution Medicines Announces Closing of Upsized Public - GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public  GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public - GlobeNewswire

Click here to get full coverage on Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire

Revolution Medicines to Participate in April 2025 Investor Conferences  GlobeNewswire

Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire

Click here to get full coverage on Revolution Medicines Secures $2 Billion Funding Agreement - TipRanks

Revolution Medicines Secures $2 Billion Funding Agreement  TipRanks

Revolution Medicines Secures $2 Billion Funding Agreement - TipRanks

Click here to get full coverage on Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - Benzinga

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?  Benzinga

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - Benzinga

Click here to get full coverage on Revolution Medicines Executives Sell Shares - TradingView

Revolution Medicines Executives Sell Shares  TradingView

Revolution Medicines Executives Sell Shares - TradingView

Click here to get full coverage on Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus

Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News  GuruFocus

Revolution Medicines (RVMD) Advances Key Clinical Trials and Strengthens Team | RVMD Stock News - GuruFocus

Click here to get full coverage on Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com

Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update  Investing.com

Earnings call transcript: Revolution Medicines sees stock surge after Q1 2025 update - Investing.com

Click here to get full coverage on Revolution Medicines Announces Pricing of Upsized $750.0 - GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $750.0  GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $750.0 - GlobeNewswire

Click here to get full coverage on Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug - TradingView

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug  TradingView

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug - TradingView

Click here to get full coverage on Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference  GlobeNewswire

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Click here to get full coverage on Revolution Medicines enters $2B funding agreement with Royalty Pharma - TipRanks

Revolution Medicines enters $2B funding agreement with Royalty Pharma  TipRanks

Revolution Medicines enters $2B funding agreement with Royalty Pharma - TipRanks

Click here to get full coverage on Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress  Investing.com

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress - Investing.com

Click here to get full coverage on Revolution Medicines stock hits 52-week low at $30.02 - Investing.com

Revolution Medicines stock hits 52-week low at $30.02  Investing.com

Revolution Medicines Inc (RVMD)

Price Chart

Key Statistics

Technicals

About RVMD

Latest News

Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress - MSN

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewswire

Revolution Medicines Insider Ups Holding During Year - simplywall.st

Advanced Charts

Top Gainers

Top Losers